April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Systemic cyclosporine treatment in primary pediatric keratoplasty. Evaluation of results.
Author Affiliations & Notes
  • Telmo Xabier Lerchundi Plaza
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Ainhoa Ibarrola Vidaurre
    Pediatrics, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Beatriz Jiménez Gómez
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Maria Sanchez Lopez
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Sandra De Fernando Aisa
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Ricardo Martinez Fernandez
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Juan A Duran
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Nerea Martínez Alday
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Jaime Etxebarria
    Ophthalmology, Hospital Universitario Cruces, Cruces/Barakaldo, Spain
  • Footnotes
    Commercial Relationships Telmo Xabier Lerchundi Plaza, None; Ainhoa Ibarrola Vidaurre, None; Beatriz Jiménez Gómez, None; Maria Sanchez Lopez, None; Sandra De Fernando Aisa, None; Ricardo Martinez Fernandez, None; Juan Duran, None; Nerea Martínez Alday, None; Jaime Etxebarria, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3134. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Telmo Xabier Lerchundi Plaza, Ainhoa Ibarrola Vidaurre, Beatriz Jiménez Gómez, Maria Sanchez Lopez, Sandra De Fernando Aisa, Ricardo Martinez Fernandez, Juan A Duran, Nerea Martínez Alday, Jaime Etxebarria; Systemic cyclosporine treatment in primary pediatric keratoplasty. Evaluation of results.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3134.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To study the characteristics, indications and outcomes of pediatric keratoplasties comparing the influence of the systemic treatment with oral cyclosporine A. All the keratoplasties, treatment and follow up were done in one Hospital.

 
Methods
 

Retrospective review of primary keratoplasties in children under 14 years old, between 1997 and 2011. Graft survival and best corrected visual acuity was evaluated in children with oral cyclosporine A treatment. The criteria for surgical indication were best corrected visual acuity less than 0.3, preferential vision less than 0.1 cycles per minute, opacity in visual axis more than 3mm, deprivation signs or difficulty to fundus visualization. The treatment with oral cyclosporine A was started as the keratoplasty was done. The initial dose was between 5 y 7 mg/kg/day , later it was regulated.

 
Results
 

A total of 17 primary keratoplasties were performed in 15 patients between 1997 and 2011. The median age was 18.6 months (minimum 18 days and maximum 13.4 years). Children were treated with oral cyclosporine A for 1 year after surgery. The median follow up is 40 months. The indications were congenital opacities in 8 eyes, acquired non traumatic opacities in 6 eyes and 3 eyes had posttraumatic scars. The graft was transparent (11/15) or with low opacity (2/15) in 86.7% (13/15) of cases at 12 months, in 64.2% of cases at 2 years and 61.6% at 3 years. At 12 months follow up only two grafts were rejected (13.3%). The median T0 at 2 weeks follow up was 140 ng/ml (DT: 46.7) and at 12 months 98 ng/ml (DT :37.3). The renal toxicity was controlled with the blood pressure measure and eGF (Schwartz) checking. The median eGFR value at 2 weeks was 133 (DT:47.3) and 158 (DT:38.4) at one year. The median duration of the oral treatment was 12.3 months. The side effects observed were: 7 childs with mild hirsutism, 4 with low gingival hyperplasia and 1 with insomnia.

 
Conclusions
 

Although the heterogeneity of the surgical indications makes difficult to compare the results of different series, oral cyclosporine A seems to be a good treatment to improve the outcomes of pediatric keratoplasty. Althought some side effects appear in our serie, it is a safe immunosuppressive agent and could improve the survival of the grafts. This is maybe the first series of cases treated with this procedure and has obtained good results.

     
Keywords: 741 transplantation • 479 cornea: clinical science • 556 infant vision  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×